Testing the drug repotrectinib for ROS1 lung cancer that has spread to the brain
Original title: Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle-stage test in people to see if the drug is safe and if it helps.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called repotrectinib in people whose lung cancer has spread to the brain.
Who this trial is for. This trial is for people with non-small cell lung cancer that has spread to the brain and is still active there. Their tumor has a change in a gene called ROS1, and the trial is testing a drug called repotrectinib.
Where it stands. The trial is looking at how safe the drug is and how well it works. It has not reported any results yet. No one knows the answer so far.
What this means, and what it doesn't
What it could mean: This trial is for a very specific group of people. Does your lung cancer have a ROS1 gene change? Has it spread to the brain? If so, you could ask your care team about this trial. Only the trial team can decide who is able to join.
What it doesn't mean: This trial is a test, not a proven treatment. Taking part does not mean the drug will help you. It is not a cure, and no one can promise that it will work.
Source: ClinicalTrials.gov, September 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.